GSK Q3 Core Earnings Beat, but Shingrix Sales Weaken
J.P. Morgan analysts say GSK’s third-quarter core earnings beat expectations, largely due to cost timing, while Shingrix sales were weaker than expected. Quarterly turnover was 1% ahead.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.